# Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Source: https://onco.cc/trials/nct03744468/  
OnCo record `nct03744468` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Alcestobart run by BeiGene, completed.

## Summary

Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03744468 by BeiGene, with 147 participants enrolled, started 2018-11-13. Conditions recorded: Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion and NSCLC for Phase 2 Dose Expansion. Interventions recorded: Surzebiclimab, Tislelizumab and Alcestobart.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03744468
- Phase: 1/2
- Setting: Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
- Sponsor: BeiGene
- Enrolled: 147

## Sources

- ClinicalTrials.gov NCT03744468: https://clinicaltrials.gov/study/NCT03744468

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Alcestobart](https://onco.cc/drugs/alcestobart/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct03744468.json